
Could Treasury’s proposed COINS Act rule make it harder for American patients to get promising new medicines? The proposed regulations would restrict a broad range of transactions with Chinese companies. That could...


There's a scientific breakthrough in your medicine cabinet. But how did it get there? At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients. From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures. In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
42%
Guest openness
Selective
Sign up to generate a grounded pitch for Making Medicine.
Signup to Generate a PitchThere's a scientific breakthrough in your medicine cabinet. But how did it get there?
Recent episodes include "Inside the COINS Act: How Treasury’s China Rule Could Reshape Drug Development" (29 October 2026, 54 minutes), "Myths vs. Facts: China, Biotech, and National Security" (22 October 2026, 32 minutes), and "Biotech Boom, Drug Lag: Japan's Innovation Paradox" (15 October 2026, 48 minutes).
Making Medicine publishes roughly weekly, with episodes averaging 37 minutes across 100 episodes.
Booking probability for Making Medicine is 42%, and the host is rated Selective on guests. Making Medicine requires a Pod Score of 80 or higher. Making Medicine's contact route on record: verified email.
The strongest fits for Making Medicine are Scientific Research & Development and Pharmaceuticals. Making Medicine has a health audience.
Making Medicine is a health podcast with 100 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

Could Treasury’s proposed COINS Act rule make it harder for American patients to get promising new medicines? The proposed regulations would restrict a broad range of transactions with Chinese companies. That could...

Are American biotech companies really sending $120 billion to China? And could restricting U.S. investment weaken America's position in the global biotech industry? As Washington debates biotechnology investment...

Japan has many of the ingredients of a world-class biotechnology ecosystem: leading scientific research, Nobel Prize-winning discoveries, and growing investment. Yet many innovative medicines reach Japanese patients...

Ohio is emerging as a major U.S. life sciences hub, with growing investment in biotech, gene therapy, biomanufacturing and pharmaceutical innovation. But what does it take to build a competitive biotech ecosystem...

Artificial intelligence could transform drug discovery and biotech, but not necessarily in the ways the biggest AI predictions suggest. Where can AI actually make drug development faster and more efficient, and where...

China’s biotech industry is expanding rapidly, reshaping clinical trials, drug development, licensing and the global competition for biomedical innovation. What can the United States learn from what’s happening in...

Why does a small molecule medicine get nine years on the market before Medicare negotiation while a biologic gets 13? And what does that four-year difference mean for the medicines that do get developed? For 9/13 Day...

Artificial intelligence is reshaping biotech, drug discovery and medicine. But how much of the AI revolution is real, how much is hype, and what could it mean for the future of American medicine? In Part 6 of our How...

Venture capital helped build America's biotech industry, but what happens when that capital stops flowing? In Episode 5 of the How America Makes Medicine series, John Stanford sits down with Michael Rome, Managing...

Why does so much pharmaceutical innovation come from small biotech companies? And how do different parts of America's medicine ecosystem work together to turn scientific discoveries into medicines for patients? In this...

Episode #32
Every breakthrough medicine begins with a scientific discovery. But turning that discovery into a *treatment* that reaches patients*requires navigating one of the most challenging journeys in medicine. Before a new...

Episode #31
Every breakthrough medicine starts somewhere. Discover how research universities, NIH funding, and American innovation change lives. Every new medicine’s journey begins long before it reaches a patient. In Episode 2 of...

How America Makes Medicine begins with the remarkable story of 250 years of American pharmaceutical innovation. Welcome to How America Makes Medicine, a new seven-part series from the Making Medicine Podcast celebrating...

🇺🇸 FDA leadership, China's growing role in clinical trials, NIH research, and biotechnology innovation are shaping the future of American medicine. This week on the Making Medicine Podcast, John Stanford breaks down...

Japan's biotech industry is at a crossroads. Drug pricing reform, clinical trials, venture capital investment, and life sciences policy are all in flux as the country tries to figure out its path forward. This week on...

Georgia's life sciences industry is growing fast. Biotech manufacturing, clinical trials, workforce development, and healthcare policy are reshaping America's innovation economy. This week on the Making Medicine...

FDA instability is reshaping biotech investment decisions in real time. Investors are recalibrating risk, pulling back, and even shifting capital abroad. In case you missed it: We are bringing one of our most critical...

China and biotech competition. Drug pricing reform. The FDA. PBMs. America’s innovation economy. This week on the Making Medicine Podcast, John Stanford sits down with Rep. Scott Peters to discuss the future of American...

What does the FDA actually look like on the inside — and why does its structure matter for drug approvals, rare disease therapies, and biotech investment? This week on the Making Medicine Podcast, host John Stanford is...

FDA instability. AI in clinical trials. China overtaking the United States in biotech development. Following news that Marty Makary has stepped down as FDA commissioner, questions around regulatory stability, scientific...
Recent guests on Making Medicine. Study who booked and why before you pitch.
Managing Partner, Prism Group
American University
physician-scientist, former Teva CEO, author of Biotech and the Balance, South African biopharmaceuticals
PMP, Colonel, U.S. Marine Corps (Ret.), Executive Director, Office of Defense & Aerospace Innovation, The Michigan Office of Defense and Aerospace Innovation
PitchCentric classifies Making Medicine under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ